Fatty acid-binding protein-2 genotype influences lipid and lipoprotein response to eicosapentaenoic acid supplementation in hypertriglyceridemic subjects

Nutrition

Volumn 26, Issue 11-12, 2010, Pages 1117-1121

  Pishva, Hamideh ^a   Mahboob, Soltan Ali ^b   Mehdipour, Parvin ^c   Eshraghian, Mohammad Reza ^a   Mohammadi Asl, Javad ^d   Hosseini, Saeed ^e   Karimi, Farzaneh ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood lipid; Eicosapentaenoic acid; Fatty acid binding protein 2; Polymorphism

Indexed keywords

ALANINE; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; FATTY ACID BINDING PROTEIN 2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THREONINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DNA POLYMORPHISM; FEMALE; GENOTYPE; HETEROZYGOTE DETECTION; HUMAN; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; APOLIPOPROTEIN C-III; CHOLESTEROL, HDL; DIETARY SUPPLEMENTS; EICOSAPENTAENOIC ACID; FATTY ACID-BINDING PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERTRIGLYCERIDEMIA; IRAN; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 77957778145     PISSN: 08999007     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nut.2009.09.028     Document Type: Article

References (36)

1. Hegele R.A. A review of intestinal fatty acid binding protein gene variation and the plasma lipoprotein response to dietary components. Clin Biochem 1998, 31:609-612.
2. Besnard P., Niot I., Bernard A., Carlier H. Cellular and molecular aspects of fat metabolism in the small intestine. Proc Nutr Soc 1996, 55:19-37.
3. Van Nieuwenhoven F.A., Van der Vusse G.J., Glatz J.F. Membrane-associated and cytoplasmic fatty acid-binding proteins. Lipids 1996, 31(Suppl):S223-S227.
4. Marin C., Perez-Jimenez F., Gomez P., Delgado J., Paniagua J.A., Lozano A., et al. The Ala54Thr polymorphism of the fatty acid-binding protein 2 gene is associated with a change in insulin sensitivity after a change in the type of dietary fat. Am J Clin Nutr 2005, 82:196-200.
5. Morcillo S., Rojo-Martinez G., Cardona F., Almaraz M. de L., de Adana M. de L., Esteva I., et al. Effect of the interaction between the fatty acid binding protein 2 gene Ala54Thr polymorphism and dietary fatty acids on peripheral insulin sensitivity: a cross-sectional study. Am J Clin Nutr 2007, 86:1232-1237.
6. Weiss E.P., Brown M.D., Shuldiner A.R., Hagberg J.M. Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol Genomics 2002, 10:145-157.
7. Baier L.J., Sacchettini J.C., Knowler W.C., Eads J., Paolisso G., Tataranni P.A., et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995, 95:1281-1287.
8. Kelley D.S., Siegel D., Vemuri M., Mackey B.E. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 2007, 86:324-333.
9. Stan S., Lambert M., Delvin E., Paradis G., O'Loughlin J., Hanley J.A., Levy E. Intestinal fatty acid binding protein and microsomal triglyceride transfer protein polymorphisms in French-Canadian youth. J Lipid Res 2005, 46:320-327.
10. Hsu H.C., Lee Y.T., Chen M.F. Effect of n-3 fatty acids on the composition and binding properties of lipoproteins in hypertriglyceridemic patients. Am J Clin Nutr 2000, 71:28-35.
11. Gaziano J.M., Hennekens C.H., O'Donnell C.J., Breslow J.L., Buring J.E. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997, 96:2520-2525.
12. Kris-Etherton P.M., Harris W.S., Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002, 106:2747-2757.
13. Arterburn L.M., Hall E.B., Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr 2006, 83. 1467S-76.
14. American Heart Association. Fish oil and omega-3 fatty acids (AHA recommendation). Texas: American Heart Association; 2006.
15. Grimsgaard S., Bonaa K.H., Hansen J.B., Nordoy A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr 1997, 66:649-659.
16. Geppert J., Kraft V., Demmelmair H., Koletzko B. Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial. Br J Nutr 2006, 95:779-786.
17. Ordovas J.M. Fast ultracentrifugation methods for the separation of plasma lipoproteins. Lipoprotein protocols 1998, 93-104. Springer-Verlag, Boston. J.M. Ordovas (Ed.).
18. Vimaleswaran K.S., Radha V., Mohan V. Thr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians. Metabolism 2006, 55:1222-1226.
19. Aalto-Setala K., Fisher E.A., Chen X., Chajek-Shaul T., Hayek T., Zechner R., et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992, 90:1889-1900.
20. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996, 37:907-925.
21. Berge R.K., Madsen L., Vaagenes H., Tronstad K.J., Gottlicher M., Rustan A.C. In contrast with docosahexaenoic acid, eicosapentaenoic acid and hypolipidaemic derivatives decrease hepatic synthesis and secretion of triacylglycerol by decreased diacylglycerol acyltransferase activity and stimulation of fatty acid oxidation. Biochem J 1999, 343(pt 1):191-197.
22. Dagnelie P.C., Rietveld T., Swart G.R., Stijnen T., Vanden Berg J.W. Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans. Lipids 1994, 29:41-45.
23. Sampath H., Ntambi J.M. Polyunsaturated fatty acid regulation of gene expression. Nutr Rev 2004, 62:333-339.
24. Jump D.B. Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci 2004, 41:41-78.
25. Jain S., Gaiha M., Bhattacharjee J., Anuradha S. Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress-a prospective preliminary study. J Assoc Phys India 2002, 50:1028-1033.
26. Pedersen H., Petersen M., Major-Pedersen A., Jensen T., Nielsen N.S., Lauridsen S.T., Marckmann P. Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes. Eur J Clin Nutr 2003, 57:713-720.
27. Barrett P.H., Watts G.F. Kinetic studies of lipoprotein metabolism in the metabolic syndrome including effects of nutritional interventions. Curr Opin Lipidol 2003, 14:61-68.
28. Abbey M., Clifton P.M., McMurchie E.J., McIntosh G.H., Nestel P.J. Effect of a high fat/cholesterol diet with or without eicosapentaenoic acid on plasma lipids, lipoproteins and lipid transfer protein activity in the marmoset. Atherosclerosis 1990, 81:163-174.
29. Dworatzek P.D.N., Hegele R.A., Wolever T.M.S. Postprandial lipemia in subjects with the threonine 54 variant of the fatty acid-binding protein 2 gene is dependent on the type of fat ingested. Am J Clin Nutr 2004, 79:1110-1117.
30. Harris W.S. N-3 fatty acids and serum lipoproteins: animal studies. Am J Clin Nutr 1997, 65. 1611S-6.
31. Fernandez M.L., West K.L. Mechanisms by which dietary fatty acids modulate plasma lipids. J Nutr 2005, 135:2075-2078.
32. Woodman R.J., Chew G.T., Watts G.F. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs 2005, 65:31-74.
33. Mori T.A., Burke V., Puddey I.B., Watts G.F., O'Neal D.N., Best J.D., Beilin L.J. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 2000, 71:1085-1094.
34. Bryhn M., Hansteen H., Schanche T., Aakre S.E. The bioavailability and pharmacodynamics of different concentrations of omega-3 acid ethyl esters. Prostaglandins Leukot Essent Fatty Acids 2006, 75:19-24.
35. Grundt H., Nilsen D.W., Hetland O., Aarsland T., Baksaas I., Grande T., Woie L. Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia. J Intern Med 1995, 237:249-259.
36. Toft I., Bonaa K.H., Ingebretsen O.C., Nordoy A., Jenssen T. Effects of n-3 polyunsaturated fatty acids on glucose homeostasis and blood pressure in essential hypertension. A randomized, controlled trial. Ann Intern Med 1995, 123:911-918.